The coordinated buying by three large passive managers suggests growing confidence in CCCC’s pipeline or valuation, potentially ahead of clinical catalysts. Traders should monitor for upcoming trial data or partnerships as potential near-term triggers.
Executive Summary
Three major institutional investors — Morgan Stanley, Wells Fargo, and UBS — increased their positions in C4 Therapeutics (CCCC) during Q4 2024, with UBS doubling its stake. The aggregate buying activity totaled $1.4M in net new investment, signaling growing institutional interest in the small-cap biotech firm.
Key Financial Metrics
Institutional Positions
Net institutional flow: $1.4M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | ADD | +65.1% | $13.8M | $563.0K |
| UBS | DOUBLED | +126.8% | $2.7M | $824.0K |
| Wells Fargo | ADD | +34.9% | $131.0K | -$22.7K |
Key Facts
- Morgan Stanley increased its stake by 65.1%, adding 1.51M shares with a value increase of $563K to a total of $13.8M.
- UBS doubled its position, increasing shares by 126.8% (423.8K shares added), growing its investment value by $824K to $2.7M.
- Wells Fargo added 9.4K shares (+34.9%), though the value of its position decreased slightly by $22,725 to $131K, likely due to share price movement during the period.
- No institutional selling was observed — all three tracked institutions were net buyers.
Financial Impact
Institutions added $1.4M in net new positions during Q4 2024, with total current holdings now at $16.7M.
Risk Factors
- All buyers are classified as mega-passive institutions, which may indicate index-driven or model-based buying rather than high-conviction active bets.
- CCCC has a small market cap ($401M), making it vulnerable to volatility if sentiment shifts or institutions rebalance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CCCC-2024-Q4 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 144 | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | — |
Aug 14, 2026 6w ago | Institutional Cluster | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | — |
Aug 11, 2026 7w ago | 8-K | $3.62 $4.18 | ▲ +15.47% | ▲ +15.87% | — |
Jun 11, 2026 16w ago | Press Release | $3.87 $3.92 | ▲ +1.29% | ▲ +0.86% | — |
May 15, 2026 19w ago | 8-K | $3.22 $3.49 | ▲ +8.39% | ▲ +6.77% | — |
May 12, 2026 20w ago | 8-K | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | — |
May 12, 2026 20w ago | Press Release | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | — |
Apr 9, 2026 25w ago | 8-K | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | — |
Apr 9, 2026 25w ago | Press Release | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | — |
Mar 25, 2026 27w ago | Press Release | $2.69 $2.70 | ▲ +0.37% | ▲ +0.62% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access